Table 1.
Patient demographics, symptom timeline, and pre‐transplant waitlist progression and support
| Pt #, sex Blood type, BMI | Variant | Comorbidities | 1st symptoms (age) | Age: ARVC Dx, HF onset | # VT ablations (age last) | Anti‐arrhythmic meds a | HF phenotype | HT eval indication (age) | Time eval to list (days) | Initial, terminal waitlist status | Support at HT | Total waitlist time (time at terminal) | Ischaemic time (min) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1, M | PKP2 | hypoTHY, GERD, IBS | VT (25) | 25, 31 | 3 (33) | Metoprolol, amio | pRV | HF (32) | 62 | 2, 1Ae | ‐ | 148 | 161 |
| O+, 25.7 | |||||||||||||
| 2, M | ‐ | ‐ | Orthopnoea/PND/oedema (40) | 40, 40 | βB, amio | RV | HF (40) | 153 | 2 b , 2 | ‐ | 308 b (‐) | 168 | |
| O−, 26.3 | |||||||||||||
| 3, M | PKP2 | ‐ | Palpitations (12) | 15, 16 | 3 (17) | Amio, βB | pRV | HF + VT (17) | 56 | 2, 1B | Milrin | 195 (104) | 196 |
| B+, 18.3 | |||||||||||||
| 4, M | ‐ | CKD | VT (14) | 14, 32 | ‐ | Amio, βB | RV | HF (32) | 391 | 2, 1Ae | ‐ | 93 (90) | 212 |
| O+, 19.2 | |||||||||||||
| 5, F | PKP2 | GERD, atrial tachycardia | VT (21) | 21, 34 | 3 (25) | Flec, βB | RV | HF (35) | 75 | 2e, 2e | ‐ | 4 (‐) | 154 |
| O−, 32.1 | |||||||||||||
| 6, F c | ‐ | Cirrhosis, atrial flutter | VT (18) | 18, 47 | 4 (35) | Sotalol | RV | HF (47) | 76 | 6, 2e | Dopa | 244 (90) | 191 |
| A+, 18.5 | |||||||||||||
| 7, F | PKP2 | hypoTHY, CKD, afib | HF (37) | 58, 37 d | ‐ | Amio, βB | BiV | HF (61) | 407 | 6, 2e | Dobut | 175 (7) | 249 |
| B+, 21.8 | |||||||||||||
| 8, M | PKP2 | hypoTHY, recent PE | Palpitations/dyspnoea (44) | 44, 65 | 1 (65) | Flec, metoprolol | RV | VT > HF (65) | 17 | 1, 1 | ECMO | 7 (‐) | 118 |
| A+, 20.2 | |||||||||||||
| 9, M | PKP2 | hypoTHY | SCA (28) | 29, 42 | 4 (30) | Dofetilide, metoprolol, sotalol, amio | RV | HF (42) | 53 | 6, 1e | ECMO | 66 (8) | 175 |
| A+, 24.1 |
Afib, atrial fibrillation; ARVC, arrhythmogenic right ventricular cardiomyopathy; BiV, biventricular failure; CKD, chronic kidney disease; dobut, dobutamine; dopa, dopamine; Dx, diagnosis; ECMO, extracorporeal membrane oxygenation; eval, evaluation; GERD, gastroesophageal reflux disease; HF, heart failure; HT, heart transplant; Hx, history; hypoTHY, hypothyroidism; IABP, intra‐aortic balloon pump; IBS, irritable bowel syndrome; milrin, milrinone; PKP2, plakophilin‐2 gene; PND, paroxysmal nocturnal dyspnoea; pRV, predominant right ventricular failure; RV, isolated right ventricular failure; SCA, sudden cardiac arrest; VT, ventricular tachycardia.
Patients are listed in heart transplant date chronological order. Grey rows represent heart transplants performed prior to the October 2018 heart transplant allocation system revision in the USA. The patient in the orange row underwent heart transplant as a paediatric patient under the paediatric heart transplant allocation system.
Italicized medications were previously tried but were discontinued because of ineffectiveness, side effects, or intolerance.
Status 2 five years prior to heart transplant but improved leading to Status 7 listing. Elapsed time in table only represents relisting as Status 2.
Patient underwent simultaneous liver transplant at the time of heart transplant.
Heart failure symptoms resolved for 10+ years before recurring.